|Metabolism||Liver (major: CYP3A4, minor: CYP3A5)|
|Elimination half-life||17–19 hours|
|Chemical and physical data|
|Molar mass||410.425 g·mol−1|
|3D model (JSmol)|
Lemborexant, sold under the brand name Dayvigo, is a medication for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. Lemborexant was approved in the United States for use by adults with insomnia in December 2019.
The time to peak levels of lemborexant is 1 to 3 hours. A high-fat and high-calorie meal has been found to delay the time to peak levels by 2 hours. Its plasma protein binding in vitro is 94%. Lemborexant is metabolized primarily by CYP3A4 and to a lesser extent by CYP3A5. The elimination half-life of lemborexant is 17 to 19 hours. The medication is excreted in feces (57%) and to a lesser extent urine (29%).
Lemborexant is sold under the brand name Dayvigo.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|